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A B S T R A C T 
Objective: To investigate the impact of skeletal-
related events on survival in patients with metastatic 
prostate cancer prescribed long-term androgen 
deprivation therapy.
Methods: This historical cohort study was conducted 
in two hospitals in Hong Kong. Patients who were 
diagnosed with metastatic prostate cancer and 
prescribed androgen deprivation therapy between 
January 2006 and December 2011 were included. 
Details of skeletal-related events and mortality were 
examined.
Results: The median follow-up was 28 (range, 1-97) 
months. Of 119 patients, 52 (43.7%) developed 
skeletal-related events throughout the study, and 
the majority received bone irradiation for pain 
control. The median actuarial overall survival and 
cancer-specific survival for patients with skeletal-
related events were significantly shorter than those 
without skeletal-related events (23 vs 48 months, 
P=0.003 and 26 vs 97 months, P<0.001, respectively). 
Multivariate analysis revealed that the adjusted 
hazard ratio of presence of skeletal-related events 
on overall and cancer-specific survival was 2.73 
(95% confidence interval, 1.46-5.10; P=0.002) and 
3.92 (95% confidence interval, 1.87-8.23; P<0.001), 
respectively. A prostate-specific antigen nadir of 
>4 ng/mL was an independent poor prognostic 
factor for overall and cancer-specific survival after 
development of skeletal-related events (hazard 
ratio=10.42; 95% confidence interval, 2.10-51.66 and 
Impact of skeletal-related events on survival 
in patients with metastatic prostate cancer 
prescribed androgen deprivation therapy
Introduction
Prostate cancer is the most common cancer 
diagnosed in men in developed countries. In the 
United States, there were 240 890 estimated new 
cases in 2011, accounting for 29% of all new cancers 
in men and over 33 000 deaths.1 According to the 
Hong Kong Cancer Registry in 2012, prostate cancer 
was the third most common cancer in men.2
New knowledge added by this study
• Skeletal-related events (SREs) in patients with metastatic prostate cancer significantly worsen their prognosis.
• The prevalence of SREs in patients with metastatic prostate cancer is high.
Implications for clinical practice or policy
• Medications such as bisphosphonate therapy and receptor activator for nuclear factor κB ligand inhibitor 
should be considered to prevent SREs in patients with metastatic prostate cancer.
Hong Kong Med J 2016;22:106–15
DOI: 10.12809/hkmj144449
KW Wong, WK Ma, CW Wong, MH Wong, CF Tsang, HL Tsu, KL Ho, MK Yiu *
1 KW Wong, MB, ChB
1 WK Ma, FHKAM (Surgery)
2 CW Wong, FHKAM (Surgery)
3 MH Wong, FHKAM (Surgery)
1 CF Tsang, MB, BS
1 HL Tsu, FHKAM (Surgery)
4 KL Ho, FHKAM (Surgery)
1 MK Yiu *, FHKAM (Surgery) 
1  Division of Urology, Department of Surgery, The University of Hong 
Kong, Pokfulam, Hong Kong
2  Baptist Hospital, Kowloon Tong, Hong Kong 
3  Department of Surgery, Pamela Youde Nethersole Eastern Hospital, Chai 
Wan, Hong Kong 
4  Private practice, Hong Kong 
* Corresponding author: yiumk2@ha.org.hk
This article was 
published on 4 Dec 
2015 at www.hkmj.org.
 The overall incidence of advanced-stage 
prostate cancer has declined in recent years, probably 
due to early detection and treatment following 
application of prostate-specific antigen (PSA) for 
prostate cancer screening.3 Nonetheless it has been 
shown that approximately 4% of patients present 
with metastatic disease at the time of diagnosis1 and 
5% present with localised or regional disease that 
ORIGINAL ARTICLE
hazard ratio=10.54; 95% confidence interval, 1.94-
57.28, respectively).
Conclusions: Skeletal-related events were common 
in men with metastatic prostate cancer. This is the first 
reported study to show that a skeletal-related event 
is an independent prognostic factor in overall and 
cancer-specific survival in patients with metastatic 
prostate cancer prescribed androgen deprivation 
therapy. A prostate-specific antigen nadir of >4 
ng/mL is an independent poor prognostic factor 
for overall and cancer-specific survival following 
development of skeletal-related events.
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正接受雄激素阻斷治療的轉移性前列腺癌患者，
其骨骼相關事件對存活率的影響
黃家榮、馬偉傑、黃振榮、王明皓、曾昭鋒、徐學良、 
何崑崙、姚銘廣
目的：探討骨骼相關事件對正接受雄激素阻斷治療的轉移性前列腺癌
患者的存活率的影響。
方法：本歷史隊列研究於香港兩間醫院內進行。2006年1月至2011年
12月期間接受雄激素阻斷治療的轉移性前列腺癌患者均被列入研究範
圍。檢視骨骼相關事件的詳細資料及死亡率。
結果：中位隨訪時間為28個月（介乎1至97個月）。研究期間，119
名患者中有52人（43.7%）出現骨骼相關事件，他們大部分接受骨
腫瘤放射治療以減輕疼痛。總生存率和癌症特異性生存率中位數方
面，有骨骼相關事件發生的比沒有骨骼相關事件發生的明顯較短 
（總生存率：23比48個月，P=0.003；癌症特異性生存率：26比97
個月，P<0.001）。多變量分析顯示有骨骼相關事件發生對於總生
存率和癌症特異性生存率的調整風險比分別為2.73（95%置信區
間：1.46-5.10；P=0.002）和3.92（95%置信區間：1.87-8.23；
P < 0 . 0 0 1） 。 骨 骼 相 關 事 件 發 生 後 ， 最 低 值 前 列 腺 特 異 抗 原
（PSA）>4 ng/mL是總生存率和癌症特異性生存率的獨立不良預後
因素，風險比分別為10.42（95%置信區間：2.10-51.66）和10.54
（95%置信區間：1.94-57.28）。
結論：骨骼相關事件常見於轉移性前列腺癌患者身上。這是首個研究
報告顯示骨骼相關事件是影響正接受雄激素阻斷治療的轉移性前列腺
癌患者的總生存率和癌症特異性生存率的獨立不良預後因素。骨骼相
關事件發生後，最低值前列腺特異抗原（PSA）>4 ng/mL是總生存率
和癌症特異性生存率的獨立不良預後因素。
eventually metastasises.4
 Bone is the major metastatic site of prostate 
cancer, and has been observed in 90% of patients 
during autopsy.4 Common sites of metastases include 
the vertebrae, pelvis, long bones, ribs, and skull. 
Bone metastases cause major morbidity in patients 
with prostate cancer. They weaken the structural 
integrity of bone, leading to an increased risk for 
skeletal-related events (SREs) such as pathological 
fracture, spinal cord compression, and severe bone 
pain requiring palliative radiotherapy or surgery to 
bone.5,6
 The prognosis of localised and regional 
prostate cancer is excellent while that of metastatic 
prostate cancer is poor. The 5-year survival rate in 
patients with metastatic disease has been reported 
to be as low as 30%1 with a mean survival of 24 to 48 
months.7,8
 Evidence of the importance of SREs for 
survival in metastatic prostate cancer is limited. 
Oefelein et al9 evaluated men with prostate cancer 
who were prescribed androgen deprivation therapy 
(ADT) regardless of staging. The relative risk of 
skeletal fracture for mortality was 7.4. In another 
retrospective study, patients with bone metastasis 
from different primary tumours were analysed.10 
In the subgroup analysis, pathological fracture 
increased risk of death by 20% in patients with 
prostate cancer although the authors failed to 
demonstrate statistical significance.10 A population-
based cohort study demonstrated that mortality in 
men with metastatic prostate cancer and SREs were 
approximately twice that of patients with no SREs.11 
Treatments for prostate cancer were, however, not 
recorded or analysed in the study.11
 The aim of this study was to investigate the 
impact of SREs on survival, specifically in patients 
with carcinoma of the prostate with bone metastasis 
prescribed long-term ADT. Prognostic factors of 
survival in patients with SREs were also investigated.
Methods
The study period was between 1 January 2006 and 
31 December 2011. Patients who were diagnosed 
with prostate cancer and bone metastasis and who 
underwent either bilateral orchiectomy or were 
prescribed a first dose of luteinising hormone 
releasing hormone analogue (LHRHa) injection 
during the study period at either Queen Mary 
Hospital or Tung Wah Hospital in Hong Kong were 
included. Patients were followed up until death or 
the last follow-up taken on 31 March 2014.
 Diagnosis of carcinoma of the prostate was 
made following transrectal ultrasound-guided 
prostate biopsy, incidental histological findings 
of transurethral resection of a prostate specimen, 
biochemical diagnosis of PSA of >100 ng/mL, or 
other histological evidence such as bone biopsy in 
patients who presented with pathological fracture. 
Presence of bone metastasis was confirmed either 
by bone scan or by cross-sectional imaging such as 
computed tomography (CT) or magnetic resonance 
imaging (MRI). Patients who had evidence of bone 
metastases at four or more sites or visceral metastasis 
were regarded as having high-volume disease. 
Patients with medical castration were prescribed 
regular LHRHa injection every 3 months. Patients 
with underlying metabolic bone disease were 
excluded from study. In this study, SRE was defined 
in patients who developed pathological fractures, 
cord compression related to bone metastasis, and/
or those who received irradiation or prophylactic 
surgery to bone metastasis.6,7 Castration-resistant 
prostate cancer (CRPC) was diagnosed when there 
were at least two consecutive rises in PSA, at least 1 
week apart, with PSA of >2 ng/mL. 
 Data were collected from the electronic clinical 
management system database in the government 
health care system. Patients who underwent bilateral 
orchiectomy or received the first dose of LHRHa 
within the study period were shortlisted, reviewed, 
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and then recruited as eligible patients according to 
the inclusion criteria. Data were collected from in-
patient and out-patient records and included age 
at diagnosis; performance status; any bone pain at 
diagnosis; imaging such as bone scan, CT, and MRI; 
volume of metastasis; details of ADT and SREs; 
history of metabolic bone disease; CRPC status; 
treatment received for prostate cancer; and date and 
causes of death. Two authors (KW Wong and CF 
Tsang) abstracted the data and were not blinded to 
the outcomes.
 Data were analysed using the Statistical Package 
for the Social Sciences (Windows version 21.0; SPSS 
Inc, Chicago [IL], US). The primary outcome was 
survival time, calculated from the date of start of 
ADT until death or the last follow-up. Survival was 
described with Kaplan-Meier curves. Univariate 
and multivariate analyses were performed with Cox 
regression model to predict prognostic factors for 
survival. The dependent variables were time to death 
(overall and cancer-specific), defined as the time 
from the start of ADT to death. Prognostic variables 
significant in the univariate analyses were entered 
into the multivariate Cox regression models.
Results
A total of 119 eligible patients were identified within 
the study period. The mean age at prostate cancer 
diagnosis was 75 (range, 49-94) years. Initial ADT 
was by bilateral orchiectomy or LHRHa injection in 
58 and 61 patients, respectively, with seven patients 
subsequently switched from injection to bilateral 
orchiectomy. The median time of follow-up was 28 
(range, 1-97) months. No patient was lost to follow-
up during the study.
 The baseline characteristics of patients are 
summarised in Table 1. When stratified according 
to the presence of SREs, the two groups did not 
differ significantly in total Gleason score of prostate 
cancer, PSA level at the time of diagnosis, PSA nadir, 
Eastern Cooperative Oncology Group (ECOG) 
performance status, volume of metastasis, presence 
of bone pain at the start of ADT, or mode of ADT. 
Patients with SREs were slightly younger at the time 
of diagnosis (73.1 vs 76.3 years; P=0.04) and had a 
shorter mean follow-up time (28.5 vs 39.1 months; 
P=0.02). More patients with SREs developed CRPC 
when compared with those who did not have SREs 
(84.6% vs 65.7%; P=0.02). 
 The treatment received by patients with 
and without SREs were compared (Table 1). Only 
treatments received prior to development of SREs 
were included in Table 1 to analyse whether the 
baseline characteristics of treatment differed before 
the development of SREs. The proportion of patients 
prescribed chemotherapy, bicalutamide, flutamide, 
ketoconazole, cyproterone acetate, and calcium 
supplement was statistically similar for the two 
groups. Only two patients in each group received 
abiraterone and denosumab therapy. No patient 
received sipuleucel-T, cabazitaxel, enzalutamide, 
radium-223, or other novel treatment for prostate 
cancer throughout the study period.
Incidence of skeletal-related events
Of 119 patients, 52 (43.7%) developed SREs. A total 
of 69 SREs were recorded—36 (69.2%) patients had 
TABLE 1.  Baseline characteristics of and treatments received in patients with and 
without SREs
SREs P value
Yes (n=52) No (n=67)
Baseline characteristic
Mean age at diagnosis (years) 73.1 76.3 0.04‡
Median total Gleason score 9 9 -
Initial PSA (ng/mL) 0.30‡
Mean 1077.1 683.8
Median 252.0 151
PSA nadir (ng/mL) 0.44‡
Mean 42.7 31.0
Median 3.0 1.5
Mean follow-up (months) 28.5 39.1 0.02‡
Mode of ADT 0.52§
LHRH analogue 27 34
Bilateral orchiectomy 25* 33†
CRPC status 44 (84.6%) 44 (65.7%) 0.02§
ECOG grade 2 or above 12 (23.1%) 11 (16.4%) 0.36§
High-volume metastasis 42 (80.8%) 46 (68.7%) 0.14§
Bone pain at the start of ADT 22 (42.3%) 18 (26.9%) 0.08§
Treatment
Chemotherapy 2 (3.8%) 0 0.18¶
Abiraterone 1 (1.9%) 1 (1.5%) -
Bisphosphonate 4 (7.7%) 7 (10.4%) 0.75¶
RANKL inhibitor 1 (1.9%) 1 (1.5%) -
Hormonal manipulation
Bicalutamide 11 (21.2%) 17 (25.4%) 0.59§
Flutamide 28 (53.9%) 48 (71.6%) 0.07§
Ketoconazole 7 (13.5%) 7 (10.4%) 0.77¶
Cyproterone acetate 4 (7.7%) 5 (7.5%) 0.53¶
Calcium supplement 5 (9.6%) 12 (18.0%) 0.29¶
Abbreviations: ADT = androgen deprivation therapy; CRPC = castration-resistant 
prostate cancer; ECOG = Eastern Cooperative Oncology Group; LHRH = luteinising 
hormone releasing hormone; PSA = prostate-specific antigen; RANKL = receptor 
activator for nuclear factor κB ligand; SREs = skeletal-related events
* 5 Patients in SRE-positive group changed to bilateral orchiectomy subsequently
† 2 Patients in SRE-negative group changed to bilateral orchiectomy subsequently
‡  Independent sample t test
§  Pearson Chi squared test
¶  Fisher’s exact test
#  Impact of skeletal-related events on survival  # 
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one SRE, 15 (28.8%) patients had two SREs, and one 
patient had three SREs. Irradiation to bone for pain 
control accounted for 47 (68.1%) events; 14 (20.3%) 
events were cord compression and there were eight 
(11.6%) events of pathological fractures without cord 
compression. No patient underwent prophylactic 
surgery for bone metastasis. With regard to timing 
of SRE development, 13 (10.9%) patients had SRE 
as the initial presentation of metastatic prostate 
cancer. The overall cumulative incidence of SREs at 
1 year and 5 years of diagnosis was 23.5% and 42.9%, 
respectively (Fig 1).
Castration-resistant status and survival
The median time required to develop CRPC status 
from the start of ADT was 9 months (Fig 2a). When 
FIG 1.  Cumulative incidence of skeletal-related events (SREs) in men with prostate cancer
FIG 2.  (a and b) Kaplan-Meier curves of patients developing CRPC status, with (b) stratified according to the presence of SREs
Abbreviations: ADT = androgen deprivation therapy; CRPC = castration-resistant prostate cancer; SREs = skeletal-related events
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stratified according to the presence of SREs, the 
median time to CRPC status from ADT initiation 
was significantly shorter in patients with SREs than 
in those without (6 vs 12 months, log-rank test, 
P=0.001; Fig 2b).
 The actuarial overall survival (OS) and cancer-
specific survival (CSS) curves are shown in Figure 3. 
The 5-year actuarial OS and CSS was 32% and 43%, 
respectively. Among men without SREs, 38 (56.7%) 
patients died, compared with 44 (84.6%) patients 
in the SRE group. When stratified according to 
presence of SREs (Fig 4), the median OS and CSS for 
patients with SREs were significantly shorter than 
that for patients without SREs (log-rank test: 23 vs 
48 months, P=0.003 and 26 vs 97 months, P<0.001, 
respectively). 
Risk factors for survival
Various possible factors that could affect survival 
were analysed (Table 2a). All treatments for prostate 
cancer received both before and after SRE were 
included. Univariate analysis revealed that in terms 
of OS, presence of SREs (P=0.003), PSA nadir of >4 
ng/mL (P<0.001), ECOG grade 2 or above (P=0.01), 
and calcium supplement (P=0.03) were significant 
risk factors. On multivariate analysis, only the 
presence of SREs and PSA nadir of >4 ng/mL 
remained statistically significant, with hazard ratio 
(HR) of 2.73 (95% confidence interval [CI], 1.46-
5.10; P=0.002) and 3.01 (95% CI, 1.54-5.90; P=0.001), 
respectively. In terms of CSS, presence of SREs 
(P<0.001), PSA nadir of >4 ng/mL (P=0.004), and 
ketoconazole therapy (P=0.05) remained significant 
risk factors on both univariate and multivariate 
analyses. The HR for the presence of SREs, PSA 
nadir of >4 ng/mL, and ketoconazole therapy was 
3.92 (95% CI, 1.87-8.23; P<0.001), 2.98 (95% CI, 1.43-
6.23; P=0.004), and 2.10 (95% CI, 1.01-4.38; P=0.05), 
respectively. 
 The median survival period after occurrence 
of SRE was 11.5 months. A post-hoc analysis for OS 
and CSS after SRE revealed PSA nadir of >4 ng/mL 
as the only independent predictor for survival after 
SRE in both univariate and multivariate analyses, 
with HR of 10.42 (95% CI, 2.10-51.66; P=0.004) and 
10.54 (95% CI, 1.94-57.28; P=0.006), respectively 
(Table 2b).
Discussion
The importance of SREs in survival of patients with 
prostate cancer with different disease stage and 
treatments was studied10-12 but not specifically in 
patients with metastatic prostate cancer prescribed 
ADT. This group of patients was selected because 
patients with metastatic prostate cancer are at risk of 
developing SREs.11 In addition, ADT is the standard 
first-line treatment for metastatic prostate cancer.12 
It has been proven to provide a clear benefit in terms 
of preventing SREs.13 Focusing on patients who are 
prescribed ADT can ensure that the effect of ADT in 
preventing SREs is balanced out during analysis. A 
study by Oefelein et al9 showed that skeletal fractures 
negatively correlate with OS in men with prostate 
cancer prescribed ADT, but it included patients with 
localised disease and all kinds of fracture including 
osteoporotic fractures. Berruti et al4 reported the 
FIG 3.  (a) Overall and (b) cancer-specific survival curves of all patients
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incidence of skeletal complications in patients with 
CRPC and bone metastasis, but failed to demonstrate 
any difference in survival between patients with and 
without skeletal complications. Multivariate analysis 
was not performed on survival either. Daniell et al14,15 
reported eight fractures in 49 patients with prostate 
cancer at various times following orchiectomy but 
did not take into account the preventive effect of 
ADT in SREs.13 In our study, patients with SREs 
had much worse OS and CSS when compared with 
those without SREs (23 vs 48 months and 26 vs 97 
months, respectively), and remained significantly 
so after multivariate Cox regression analysis. To 
our knowledge, this is the first reported study to 
investigate the impact of SREs on survival in this 
homogeneous group of patients.
 The baseline characteristics were similar 
between patients with or without SREs except that 
those with SREs were slightly younger at diagnosis 
(73.1 vs 76.3 years; P=0.04). This, however, does 
not affect data interpretation since age at diagnosis 
was not a significant factor in subsequent analyses 
for both OS and CSS. In our targeted group of 
patients with metastatic prostate cancer prescribed 
ADT, the presence of SREs was first shown to be an 
independent predictive factor for OS and CSS with 
a notable HR of 2.73 and 3.92 respectively, taking 
into account baseline cancer characteristics, ECOG 
performance status, development of CRPC status, 
and different treatments received. In addition, PSA 
nadir was found to be another predictive factor 
for OS and CSS. This finding has been reported in 
previous studies16 although most included patients 
who were heterogeneous in terms of clinical stage 
of prostate cancer. Kitagawa et al16 showed that 
PSA nadir of >4 ng/mL was associated with HR of 
5.22 (95% CI, 2.757-9.89; P<0.001) in OS in patients 
with prostate cancer. The cohort, however, included 
patients with either locally advanced non-metastatic 
disease or metastatic disease. Park et al17 reported 
that a higher PSA nadir level correlated with shorter 
CSS. Similar to the previous study,16 patients with 
lymph node metastasis were also included. In 
another retrospective study,18 a high PSA nadir level 
was shown to be associated with shorter OS in a 
homogeneous group of patients with metastatic 
prostate cancer prescribed ADT. Nonetheless only 
87 patients were included in the study. In our study, 
in patients who developed SREs, PSA nadir was the 
only predictive factor for both OS and CSS with HR 
of 10.42 and 10.54, respectively. This is previously 
unreported.
 Various treatments have been proven to improve 
OS in patients with metastatic prostate cancer, 
FIG 4.  Kaplan-Meier survival curves of all patients on (a) overall survival and (b) cancer-specific survival, stratified according to the presence of 
skeletal-related events (SREs)
100
90
80
70
60
50
40
30
20
10
0
O
ve
ra
ll 
su
rv
iv
al
 (
%
)
Follow-up period (months)
0 10 20 30 40 50 60 70 80 90 100
No
Yes
No-censored
Yes-censored
SREs
100
90
80
70
60
50
40
30
20
10
0
C
an
ce
r-
sp
ec
ifi
c 
su
rv
iv
al
 (
%
)
Follow-up period (months)
0 10 20 30 40 50 60 70 80 90 100
No
Yes
No-censored
Yes-censored
SREs
(a) (b)
  #  Wong et al #
112 Hong Kong Med J  ⎥  Volume 22 Number 2  ⎥  April 2016  ⎥  www.hkmj.org
Abbreviations: ADT = androgen deprivation therapy; CI = confidence interval; CRPC = castration-resistant prostate cancer; ECOG = Eastern Cooperative 
Oncology Group; PSA = prostate-specific antigen; SRE = skeletal-related events
TABLE 2.  Cox regression analysis of different factors on overall and cancer-specific survival in (a) all patients and (b) patients with SREs
(b)
Factor Overall survival Cancer-specific survival
P value Hazard 
ratio
95% CI P value Hazard 
ratio
95% CI
Univariate Multivariate Univariate Multivariate
Presence of SREs 0.003 0.002 2.73 1.46-5.10 <0.001 <0.001 3.92 1.87-8.23
Age at diagnosis >70 years 0.402 0.45
Initial PSA level >100 ng/mL 0.055 0.41
PSA nadir >4 ng/mL <0.001 0.001 3.01 1.54-5.90 <0.001 0.004 2.98 1.43-6.23
Gleason score ≥8 0.33 0.11
CRPC status 0.09 0.01 0.07
ECOG grade 2 or above 0.01 0.10 0.10
High-volume metastasis 0.31 0.27
Bone pain at the start of ADT 0.69 0.54
Chemotherapy 0.24 0.39
Bisphosphonate 0.64 0.23
Bicalutamide 0.39 0.92
Flutamide 0.83 0.72
Ketoconazole 0.09 0.01 0.05 2.10 1.01-4.38
Cyproterone acetate 0.88 0.77
Calcium supplement 0.03 0.13 0.30
Factor Overall survival Cancer-specific survival
P value Hazard 
ratio
95% CI P value Hazard 
ratio
95% CI
Univariate Multivariate Univariate Multivariate
Timing of SREs (≤12 months after 
commencement of ADT)
0.55 0.34
No. of SRE >1 0.40 0.57
Age at diagnosis >70 years 0.56 0.50
Initial PSA level >100 ng/mL 0.60 0.87
PSA nadir >4 ng/mL 0.001 0.004 10.42 2.10-51.66 0.02 0.006 10.54 1.94-57.28
Gleason score ≥8 0.06 0.051
CRPC status 0.53 0.98
ECOG grade 2 or above 0.60 0.24
High-volume metastasis 0.06 0.14
Bone pain at the start of ADT 0.33 0.14
Chemotherapy 0.05 0.98 0.08
Bisphosphonate 0.72 0.61
Bicalutamide 0.26 0.46
Flutamide 0.43 0.19
Ketoconazole 0.48 0.40
Cyproterone acetate 0.18 0.20
Calcium supplement 0.67 0.29
Prophylactic radiation 0.38 0.31
Cord compression 0.61 0.72
Pathological fracture 0.06 0.04 0.33
(a)
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including docetaxel,19 cabazitaxel,20 abiraterone,21-23 
sipuleucel-T,24 and enzalutamide.25,26 Various bone-
modulating agents have also been studied for patients 
with bone metastasis. Bisphosphonate therapy has 
been shown to improve bone mineral density and 
quality of life,27,28 and reduce the incidence of SREs 
in patients with metastatic CRPC in a randomised 
controlled trial (RCT), although there was no proven 
survival benefit.6 The receptor activator for nuclear 
factor κB ligand (RANKL) inhibitor denosumab is 
another bone-modulating agent proven to reduce 
the incidence of SREs in metastatic CRPC patients 
but also without survival benefit.29,30 Radium-223, 
a bone-seeking calcium-mimicking alpha emitter, 
was shown in a RCT31 to not only delay first 
symptomatic SRE, but also improve OS. Therefore, 
when investigating the incidence of SRE and survival 
in these groups of patients, the aforementioned 
treatments have to be taken into account. In our 
study, treatments received by patients without SREs 
and in patients prior to development of SREs were 
statistically similar (Table 1). The number of patients 
prescribed chemotherapy or novel hormonal agents 
was relatively small in our series. Sipuleucel-T, 
enzalutamide, and radium-223 were not available 
in this locality during the study period. Denosumab 
and abiraterone therapies were used by only two 
patients in each group as these medications were 
not subsidised by the local government and were 
not affordable for many patients. Docetaxel has 
been shown to improve bone pain and OS in a phase 
III RCT.19 After development of SREs, six more 
patients received chemotherapy in our series. All 
but one patient received docetaxel. The remaining 
patient received estramustine and etoposide before 
development of SREs. The fact that all patients 
prescribed docetaxel were in the SRE group suggests 
that its potential benefit in improving OS has been 
offset by SREs and so this is not a confounding factor 
in our study. 
 The overall prevalence of bisphosphonate 
therapy was low (17%). Nine patients received 
bisphosphonate therapy only after development of 
SREs. In fact, in patients receiving bisphosphonate 
therapy, two out of seven patients without SREs 
and six out of 13 patients with SREs only received 
one dose of bisphosphonate due to various 
reasons, including side-effects of the medication, 
affordability, and early mortality after medication. 
With the heterogeneous timing of start and duration 
of therapy, we cannot accurately comment on the 
benefit of bisphosphonate in our series. No further 
patient received RANKL inhibitor or abiraterone 
after development of SREs.
 Since the pre-chemotherapy era, the concept of 
complete androgen blockade with classic hormonal 
manipulation by both steroidal anti-androgen, such 
as cyproterone acetate,32 and non-steroidal anti-
androgen (such as bicalutamide,33 flutamide,34 and 
nilutamide35) has been widely adopted when patients 
develop CRPC status. This practice remains in use 
in this locality despite the fact that no associated 
survival benefit has ever been reported12 due to the 
side-effects and availabilities of aforementioned 
novel treatments for CRPC. Ketoconazole, a broad-
spectrum imidazole antifungal agent, was previously 
the hormonal treatment of choice after anti-androgen 
withdrawal for complete androgen blockade.35 
It works by preventing adrenal steroidogenesis 
with inhibition of the enzyme cytochrome P450 
14 alpha-demethylase.36 Bicalutamide, flutamide, 
cyproterone acetate, and ketoconazole were used in 
our centre for hormonal manipulation. Interestingly, 
ketoconazole use appeared to have a deleterious 
effect on CSS even with multivariate Cox regression 
in our study. This result contradicts that of a phase 
III RCT35 which showed positive PSA and objective 
response but no survival benefit or harm. As our 
study was retrospective in nature, the implication of 
ketoconazole use is doubtful based on the results of 
this study and requires further evaluation.
 With a median follow-up of 28 months, the 
incidence of SREs in men with metastatic prostate 
cancer was high (43.7%) and is comparable with 
43.6% reported from the Danish group population-
based cohort study with similar follow-up period.11 
The median time to CRPC status from first ADT 
was 9 months, which is 5.7 months shorter than the 
control arm of the CHAARTED trial.37 This may 
be explained by the fact that the CHAARTED trial 
included patients prescribed ADT for less than 24 
months but those with disease progression within 12 
months were excluded. 
 We obtained local data of the natural history 
of metastatic prostate cancer with or without SREs 
and the impact of SREs on survival. A PSA nadir 
of >4 ng/mL was an independent poor prognostic 
factor for OS and CSS after development of SREs. 
Its clinical use in terms of predicting prognosis 
and patient counselling is highly feasible. Based 
on our results, prevention of SREs in patients with 
metastatic prostate cancer may translate to longer 
survival. Nonetheless most bone-targeting therapies, 
including bisphosphonate therapy and RANKL 
inhibitors, have failed to demonstrate survival benefit 
even though they prevent SREs.6,30,34,38 Radium-223 
appears to hold promise as it delays symptomatic 
SREs by 5.8 months and improves OS by 3.8 months 
in metastatic prostate cancer patients.31 Further 
studies are needed in this field.
 There are several limitations in this study. This 
was a retrospective study with small sample size so 
statistical power is limited. There are even fewer 
patients in post-hoc analysis. The data collected 
may not accurately reflect the condition of patients 
because the follow-up protocol was not standardised. 
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Furthermore, the data abstraction process was not 
blinded. For better presentation of data, several 
factors such as PSA nadir, initial PSA, and age at 
diagnosis were analysed as categorical data. This 
could lead to information bias. The definition of 
CRPC was less stringent than that suggested from 
international guidelines12 because testosterone level 
and follow-up imaging such as bone scans were 
not routinely performed due to limited resources. 
Potential confounding factors for survival such as 
smoking and co-morbidity were also not included in 
the study and may have affected the validity of the 
results. The small number of patients prescribed 
novel treatments or bone-modulating agents did 
not allow a comprehensive understanding of their 
influence on SRE occurrence. Further prospective 
trials with a large cohort size are necessary.
Conclusions
Skeletal-related events were common in men with 
metastatic prostate cancer and were first shown by 
this study to be an independent prognostic factor 
of OS and CSS in patients with metastatic prostate 
cancer prescribed ADT. A PSA nadir of >4 ng/mL is 
an independent poor prognostic factor for OS and 
CSS following development of SREs.
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